Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791699 | 1.00 | EGFR (0.38) | EGFRMAP3K7IRAK4KDM4EALDH1A1 | |
| SCHEMBL18791852 | 0.90 | ALK (0.37) | EGFRMAP3K7IRAK4KDM4EALDH1A1 | |
| SCHEMBL20110999 | 0.90 | ALK (0.37) | EGFRMAP3K7IRAK4KDM4EALDH1A1 | |
| SCHEMBL18792008 | 0.89 | EGFR (0.41) | EGFRMAP3K7IRAK4ALKIRAK1 | |
| SCHEMBL20111117 | 0.89 | EGFR (0.41) | EGFRMAP3K7IRAK4ALKIRAK1 | |
| SCHEMBL18791703 | 0.89 | EGFR (0.41) | EGFRMAP3K7IRAK4ALKIRAK1 | |
| SCHEMBL18791696 | 0.89 | ALK (0.36) | EGFRKDM4EALDH1A1HPGDHIF1A | |
| SCHEMBL20110985 | 0.88 | EGFR (0.40) | EGFRMAP3K7IRAK4IRAK1TRPV4 | |
| SCHEMBL18791988 | 0.88 | EGFR (0.40) | EGFRMAP3K7IRAK4IRAK1TRPV4 | |
| SCHEMBL18791991 | 0.88 | EGFR (0.40) | EGFRMAP3K7IRAK4IRAK1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885MAP3K7 306/4885IRAK4 2954/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885MAP3K7 306/4885IRAK4 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.